LifeVantage Corp

LifeVantage Corp(LFVN)の株式分析

$5.175

+0.128 (+2.48%)終値時点

Loading chart…
高値
5.320
始値
5.125
出来高加重平均価格
5.20
出来高
24.27K
時価総額
82.81M
安値
5.090
売買代金
126.06K
EV/EBITDA(TTM)
7.49

LifeVantage Corporation is an activation company, which is engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. The Company’s line of scientifically validated activators includes the flagship Protandim family of products, TrueScience Liquid Collagen, the newest MindBody GLP-1 System, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System , as well as AXIO nootropic energy drink mixes, the full TrueScience line of skin and hair care products, and Petandim, a pet supplement formulated to combat oxidative stress in dogs. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand and Singapore.

www.lifevantage.com

AI分析 of LifeVantage Corp (LFVN)

中立

LifeVantage Corp (LFVN) is currently not a strong buy due to its recent performance and financial indicators. The current price is $5.87, which is significantly below its 52-week high of $11.71, indicating potential for recovery but also substantial risk. The RSI is at 43.11, suggesting it is not yet oversold, and the forward P/E ratio is high at 37.45, reflecting concerns about future earnings growth. Additionally, the company reported a 23.1% revenue decline in Q4 2026, which raises red flags about its financial health. The main risk is the high short interest at 28.46%, indicating skepticism from investors about its recovery prospects. Overall, while there may be some upside potential, the current indicators suggest a cautious approach is warranted.

バリュエーション指標

LifeVantage Corp(LFVN)の現在の予想PERは37.45で、5年平均は15.25です。

予想PER

割高
5年平均 P/E
15.25
現在のP/E
37.45
割高
27.08
割安
3.42

予想EV/EBITDA

適正
5年平均 EV/EBITDA
5.38
現在のEV/EBITDA
7.49
割高
8.08
割安
2.69

予想PSR

適正
5年平均 P/S
0.44
現在のP/S
0.45
割高
0.64
割安
0.24

Alphio AI による LFVN の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%LFVN

$16.23

シナリオ価格

基

基本

基本 · 50%LFVN

$13.81

シナリオ価格

弱

弱気

弱気 · 25%LFVN

$12.31

シナリオ価格

イベントタイムライン

2026-08-27 (ET)

20:00:00

Nvidia's Strong Earnings Boost Tech Stocks

16:30:00

LifeVantage Q4 Revenue at $42.38M, Below Consensus

2026-06-29 (ET)

09:00:00

KULR Technology Group Borrow Rate Increases to 61.61%

2026-06-26 (ET)

09:00:00

KULR Technology Group Borrow Rate Increases to 65.52%

2026-06-24 (ET)

09:00:00

Significant Increases in Borrow Rates for Liquid Options

ニュース

LFVN のよくある質問 — Alphio AI が回答

LifeVantage Corporation is an activation company, which is engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. The Company’s line of scientifically validated activators includes the flagship Protandim family of products, TrueScience Liquid Collagen, the newest MindBody GLP-1 System, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System , as well as AXIO nootropic energy drink mixes, the full TrueScience line of skin and hair care products, and Petandim, a pet supplement formulated to combat oxidative stress in dogs. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand and Singapore. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

LifeVantage Corp (LFVN) is currently not a strong buy due to its recent performance and financial indicators. The current price is $5.87, which is significantly below its 52-week high of $11.71, indicating potential for recovery but also substantial risk. The RSI is at 43.11, suggesting it is not yet oversold, and the forward P/E ratio is high at 37.45, reflecting concerns about future earnings growth. Additionally, the company reported a 23.1% revenue decline in Q4 2026, which raises red flags about its financial health. The main risk is the high short interest at 28.46%, indicating skepticism from investors about its recovery prospects. Overall, while there may be some upside potential, the current indicators suggest a cautious approach is warranted.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める